Prelude Therapeutics Incorporated Share Price
NASDAQ: PRLD | Small CapPrelude Therapeutics Incorporated Stock Performance
Open $4.54 | Prev. Close $4.54 | Circuit Range N/A |
Day Range $4.50 - $4.71 | Year Range $0.76 - $5.67 | Volume 6,459 |
Average Traded $4.62 |
Prelude Therapeutics Incorporated Share Price Today
As of 9 August 2026, Prelude Therapeutics Incorporated's share price is $4.67. The stock opened at $4.54, compared to its previous close of $4.54. During today's trading session, Prelude Therapeutics Incorporated's share price traded between $4.50 and $4.71, with an average price of $4.60. Over the past 52 weeks, the stock has recorded a high of $5.67 and a low of $0.76. In terms of performance, Prelude Therapeutics Incorporated's share price has risen by 69.02% over the last six months and is up 276.21% on a year-on-year basis.
Prelude Therapeutics Incorporated Share Price Chart
Prelude Therapeutics Incorporated Stock Fundamentals & Key Indicators
Market Cap $359.00M | PE Ratio (TTM) -3.62 | Dividend Yield N/A |
EPS (TTM) $-1.29 | Revenue (TTM) $12.14M | Return On Equity (TTM) -144.96% |
Profit Margin -819.59% | Debt to Equity 0.77 | Quarterly Earnings Growth YoY N/A |
Prelude Therapeutics Incorporated Quarterly Profit & Loss
All figures in USD
Prelude Therapeutics Incorporated Annual Profit & Loss
All figures in USD
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Incorporated Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $4.61 | $4.54 | -1.52% |
Jul 2026 | $5.27 | $4.61 | -13.26% |
Jun 2026 | $3.86 | $5.32 | +35.24% |
May 2026 | $5.01 | $3.93 | -24.28% |
Apr 2026 | $3.60 | $5.19 | +52.65% |
Mar 2026 | $2.74 | $3.40 | +23.19% |
Feb 2026 | $1.88 | $2.76 | +48.39% |
Jan 2026 | $2.80 | $1.86 | -35.64% |
Dec 2025 | $1.52 | $2.89 | +72.54% |
Nov 2025 | $1.62 | $1.68 | +5.35% |
Oct 2025 | $1.62 | $1.59 | +10.42% |
Sep 2025 | $1.16 | $1.44 | +16.13% |